LJUBLJANA (Slovenia), May 21 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] said on Thursday it sees its 2020 profit at 210 million euro ($231 million).
The company did not provide comparative figures in a statement filed with the Ljubljana bourse. Yet, it has reported earlier this year that its consolidated net profit rose 40% to 244.3 million euro in 2019.
On Thursday, Krka also said it estimates its sales of products and services at 1.52 billion euro this year, with exports accounting for some 94% of total sales.
According to its earlier report, consolidated sales revenue was up 12% to 1.49 billion euro in 2019.
In 2020, prescription pharmaceuticals are expected to remain the most important product group, comprising 83% of overall sales, the company said.
"We plan to allocate 134 million euro to investments, primarily for expanding and modernising production facilities and infrastructure," it added, referring to this year's plans.
At the same time, the total number of employees in Slovenia and abroad is projected to grow by 3% in 2020.
Krka has production facilities in Slovenia, Russia, Poland, Croatia and Germany, and around 30 international subsidiaries involved with other activities such as marketing and sales.
The company's shares closed up 3.12% to 79.40 euro on Thursday on the Ljubljana bourse.
($=0.9109 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here